HOME >> MEDICINE >> NEWS
PENN researchers use robotic surgery

(Philadelphia, PA) For patients with cancer of the mouth and throat, surgery is a frequent course of treatment, often leading to speech and swallowing dysfunction and external scarring. Researchers from the University of Pennsylvania School of Medicine's Department of Otorhinolaryngology/Head and Neck Surgery, have completed two studies the most comprehensive and largest to date that demonstrate the effective use of the daVinci Surgical Robotic System to perform Trans-Oral Robotic Surgery (TORS) which greatly reduces surgical trauma for patients. Their initial findings will be presented Monday, May 16th at 11:45 a.m., at the combined annual meetings of otorhinolaryngology (ear, nose and throat) experts the Triologic Society, May 13th through16th, in Boca Raton, Florida.

PENN physicians anticipate that the application of the daVinci System to treat mouth and throat cancers will allow for complete tumor removal while helping to preserve voice and swallowing function. "The daVinci Robot has been FDA-approved and successfully integrated into cardiac and urologic surgery. Patients are reaping the benefits with decreased bleeding, less pain, and are able to return to work sooner," said otorhinolaryngologist Neil G. Hockstein, MD, who served as lead investigator for both studies. "I saw the potential to apply the attributes of surgical robotics to the treatment of head and neck cancer and we've successfully devised novel approaches to introduce the robotic arms through the mouth into the throat and voice box."

For head and neck tumors, treatments often involve a combination of surgery, radiation therapy, and chemotherapy. In many cases, surgery offers the greatest chance of cure. Conventional cancer surgery can consist of an almost ear-to-ear incision across the throat or splitting the jaw in half. This can result in speech and swallowing deficits for patients. "The research we've done to date suggests that TORS has great potential to improve the wa
'"/>

Contact: Olivia Fermano
olivia.fermano@uphs.upenn.edu
215-980-5370
University of Pennsylvania School of Medicine
13-May-2005


Page: 1 2 3

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
3. Penn researchers discover novel pathway for increasing good cholesterol
4. Theory of facial aging gets a facelift from UT Southwestern researchers
5. UIC researchers to develop new drugs to fight bioterrorism
6. UQ researchers discover some of the oldest forms of life
7. U of M researchers discover new method to combat HIV
8. U of M researchers assess effectiveness of computerized physician order entry system
9. Nepalese researchers identify cost-effective treatment for drug-resistant typhoid
10. Physician-researchers often less successful in obtaining NIH funding
11. UCLA researchers develop new nanomaterials to deliver anti-cancer drugs to cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2017)... ... ... Salveo for life, a company that distributes an effervescent lime-flavored drink called ... part of its presence to expand its market reach. , Using a formula developed ... nasty toxins as a result of drinking alcohol, eliminating those toxins quickly, whilst supporting ...
(Date:1/21/2017)... ... January 21, 2017 , ... Seamild, the largest manufacturer of oats ... of its owner and founder. As Oat is recognized globally as one of the ... personally as he believes it is a move to sow the seed of good ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual meeting ... family, friends, and community. “Coming Home 2017” will be held on Friday ...
(Date:1/21/2017)... Rosa, CA (PRWEB) , ... January 21, 2017 ... ... the opening of its new medical office in Petaluma, located at 167 Lynch ... casting room, access to SRO sports medicine and rehabilitation services and ...
(Date:1/21/2017)... ... January 21, 2017 , ... The ... Dr. Dan Holtzclaw in media for its creos™ line of bone regenerative products. ... Dr. Holtzclaw in which he utilizes creos™ allo.gain™ bone graft for a variety ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... 2017 ARMO BioSciences, Inc., a late-stage immuno-oncology ... Company,s lead investigational immuno-oncology drug AM0010 (PEGylated Interleukin-10) at ... Society of Clinical Oncology (ASCO), taking place January 19-21, ... "AM0010 induces the expansion of novel ... cells in the blood and tumors of our patients," ...
(Date:1/21/2017)... Research and Markets has announced the addition of the "Advanced ... End User - Forecast to 2025" report to their offering. ... The Global Advanced ... around 7.8% over the next decade to reach approximately $330.70 billion ... markets for Advanced Drug Delivery across all the given segments on ...
(Date:1/20/2017)... DUBLIN , Jan 20, 2017 ... Laboratory Testing Market By Type ([CBC, HGB/HCT, BMP, BUN Creatinine, Electrolyte ... Panel), By End-use, And Segment Forecasts, 2013 - 2024" report ... ... USD 198.5 billion by 2024 Introduction of innovative solutions ...
Breaking Medicine Technology:
Cached News: